Literature DB >> 23034928

Concentration ratios of methamphetamine to amphetamine in blood can help to distinguish use of methamphetamine from various mixtures of the two stimulants.

A W Jones1, A Holmgren.   

Abstract

Using a forensic toxicology database, the authors investigated cases of driving under the influence of drugs (DUID) if methamphetamine (MA) was identified in the blood samples (N = 9,310). The concentrations of MA and amphetamine (AM) in blood were determined after liquid-liquid extraction by gas chromatography-mass spectrometry at limits of quantitation of 0.03 mg/L for both stimulants. In 814 cases, AM was negative in blood and MA was positive at mean (median) and highest concentrations of 0.19 mg/L (0.11 mg/L) and 3.4 mg/L, respectively. Both amines were present in blood in 8,496 cases at concentrations of 0.54 mg/L (0.35 mg/L) and 10.4 mg/L for AM and 0.41 mg/L (0.22 mg/L) and 5.6 mg/L for MA. However, the correlation between AM and MA was low and insignificant (r = -0.13) in the whole material. The coefficient of correlation increased to r = 0.41 (P < 0.001) when the MA/AM concentration ratio was >1. When MA/AM ratios were selected at intervals of 1.0 (e.g., >3.0 and <4.0 up to >9.0 and <10.0), the correlation between AM and MA was r = 0.99 (P < 0.001). Such cases represent the use of MA without contamination from AM, and the mean (median) and highest concentrations of this secondary amine in blood of DUID suspects were 0.72 mg/L (0.56 mg/L) and 4.2 mg/L, respectively.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23034928     DOI: 10.1093/jat/bks075

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  4 in total

1.  Medico-legal assessment of methamphetamine and amphetamine serum concentrations-what can we learn from survived intoxications?

Authors:  Marco Weber; Rüdiger Lessig; Carolin Richter; Axel P Ritter; Ilona Weiß
Journal:  Int J Legal Med       Date:  2017-05-16       Impact factor: 2.686

2.  Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [F-18]FEPPA.

Authors:  Gausiha Rathitharan; Jennifer Truong; Junchao Tong; Tina McCluskey; Jeffrey H Meyer; Romina Mizrahi; Jerry Warsh; Pablo Rusjan; James L Kennedy; Sylvain Houle; Stephen J Kish; Isabelle Boileau
Journal:  Addict Biol       Date:  2020-02-04       Impact factor: 4.280

Review 3.  Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts.

Authors:  Atul P Daiwile; Subramaniam Jayanthi; Jean Lud Cadet
Journal:  Neurosci Biobehav Rev       Date:  2022-04-20       Impact factor: 9.052

4.  Prevalence of psychoactive substance use among acutely hospitalised patients in Oslo and Moscow: a cross-sectional, observational study.

Authors:  Danil Gamboa; Benedicte Jørgenrud; Evgeny A Bryun; Vigdis Vindenes; Evgenya A Koshkina; Aleksei V Nadezhdin; Saranda Kabashi; Elena J Tetenova; Thomas Berg; Anna Armika Tussilago Nyman; Alexey J Kolgashkin; Aleksei E Petukhov; Sergey N Perekhodov; Elena N Davydova; Anners Lerdal; Gudmund Nordby; Stig Tore Bogstrand
Journal:  BMJ Open       Date:  2020-09-17       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.